• Je něco špatně v tomto záznamu ?

Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture

K. Michalova, M. Tretiakova, K. Pivovarcikova, R. Alaghehbandan, D. Perez Montiel, M. Ulamec, A. Osunkoya, K. Trpkov, G. Yuan, P. Grossmann, M. Sperga, I. Ferak, J. Rogala, J. Mareckova, T. Pitra, J. Kolar, M. Michal, O. Hes,

. 2020 ; 44 (-) : 151448. [pub] 20191214

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028535

Although typically arranged in solid alveolar fashion, chromophobe renal cell carcinoma (RCC) may also show several other architectural growth patterns. We include in this series 8 chromophobe RCC cases with prominent papillary growth, a pattern very rarely reported or only mentioned as a feature of chromophobe RCC, which is lacking wider recognition The differential diagnosis of such cases significantly varies from the typical chromophobe RCC with its usual morphology, particularly its distinction from papillary RCC and other relevant and clinically important entities. Of 972 chromophobe RCCs in our files, we identified 8 chromophobe RCCs with papillary growth. We performed immunohistochemistry and array Comparative Genomic Hybridisation (aCGH) to investigate for possible chromosomal aberrations. Patients were 3 males and 5 females with age ranging from 30 to 84 years (mean 57.5, median 60 years). Tumor size was variable and ranged from 2 to 14 cm (mean 7.5, median 6.6 cm). Follow-up was available for 7 of 8 patients, ranging from 1 to 61 months (mean 20.1, median 12 months). Six patients were alive with no signs of aggressive behavior, and one died of the disease. Histologically, all cases were composed of dual cell population consisting of variable proportions of leaf-like cells with pale cytoplasm and eosinophilic cells. The extent of papillary component ranged from 15 to 100% of the tumor volume (mean 51%, median 50%). Sarcomatoid differentiation was identified only in the case with fatal outcome. Immunohistochemically, all tumors were positive for CK7, CD117 and Hale's Colloidal Iron. PAX8 was positive in 5 of 8 cases, TFE3 was focally positive 3 of 8 tumors, and Cathepsin K was focally positive in 2 of 8 tumors. All cases were negative for vimentin, AMACR and HMB45. Fumarate hydratase staining was retained in all tested cases. The proliferative activity was low (up to 1% in 7, up to 5% in one case). Three cases were successfully analyzed by aCGH and all showed a variable copy number variation profile with multiple chromosomal gains and losses. CONCLUSIONS: Chromophobe RCC demonstrating papillary architecture is an exceptionally rare carcinoma. The diagnosis can be challenging, although the cytologic features are consistent with the classic chromophobe RCC. Given the prognostic and therapeutic implications of accurately diagnosis other RCCs with papillary architecture (i.e., Xp11.2 translocation RCC, FH-deficient RCC), it is crucial to differentiate these cases from chromophobe RCC with papillary architecture. Based on this limited series, the presence of papillary architecture does not appear to have negative prognostic impact. However, its wider recognition may allow in depth studies on additional examples of this rare morphologic variant.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028535
003      
CZ-PrNML
005      
20210114154156.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.anndiagpath.2019.151448 $2 doi
035    __
$a (PubMed)31918172
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Michalova, Kvetoslava $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.
245    10
$a Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture / $c K. Michalova, M. Tretiakova, K. Pivovarcikova, R. Alaghehbandan, D. Perez Montiel, M. Ulamec, A. Osunkoya, K. Trpkov, G. Yuan, P. Grossmann, M. Sperga, I. Ferak, J. Rogala, J. Mareckova, T. Pitra, J. Kolar, M. Michal, O. Hes,
520    9_
$a Although typically arranged in solid alveolar fashion, chromophobe renal cell carcinoma (RCC) may also show several other architectural growth patterns. We include in this series 8 chromophobe RCC cases with prominent papillary growth, a pattern very rarely reported or only mentioned as a feature of chromophobe RCC, which is lacking wider recognition The differential diagnosis of such cases significantly varies from the typical chromophobe RCC with its usual morphology, particularly its distinction from papillary RCC and other relevant and clinically important entities. Of 972 chromophobe RCCs in our files, we identified 8 chromophobe RCCs with papillary growth. We performed immunohistochemistry and array Comparative Genomic Hybridisation (aCGH) to investigate for possible chromosomal aberrations. Patients were 3 males and 5 females with age ranging from 30 to 84 years (mean 57.5, median 60 years). Tumor size was variable and ranged from 2 to 14 cm (mean 7.5, median 6.6 cm). Follow-up was available for 7 of 8 patients, ranging from 1 to 61 months (mean 20.1, median 12 months). Six patients were alive with no signs of aggressive behavior, and one died of the disease. Histologically, all cases were composed of dual cell population consisting of variable proportions of leaf-like cells with pale cytoplasm and eosinophilic cells. The extent of papillary component ranged from 15 to 100% of the tumor volume (mean 51%, median 50%). Sarcomatoid differentiation was identified only in the case with fatal outcome. Immunohistochemically, all tumors were positive for CK7, CD117 and Hale's Colloidal Iron. PAX8 was positive in 5 of 8 cases, TFE3 was focally positive 3 of 8 tumors, and Cathepsin K was focally positive in 2 of 8 tumors. All cases were negative for vimentin, AMACR and HMB45. Fumarate hydratase staining was retained in all tested cases. The proliferative activity was low (up to 1% in 7, up to 5% in one case). Three cases were successfully analyzed by aCGH and all showed a variable copy number variation profile with multiple chromosomal gains and losses. CONCLUSIONS: Chromophobe RCC demonstrating papillary architecture is an exceptionally rare carcinoma. The diagnosis can be challenging, although the cytologic features are consistent with the classic chromophobe RCC. Given the prognostic and therapeutic implications of accurately diagnosis other RCCs with papillary architecture (i.e., Xp11.2 translocation RCC, FH-deficient RCC), it is crucial to differentiate these cases from chromophobe RCC with papillary architecture. Based on this limited series, the presence of papillary architecture does not appear to have negative prognostic impact. However, its wider recognition may allow in depth studies on additional examples of this rare morphologic variant.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a papilární karcinom $x diagnóza $x genetika $x patologie $7 D002291
650    _2
$a karcinom z renálních buněk $x diagnóza $x genetika $x patologie $7 D002292
650    _2
$a chromozomální aberace $7 D002869
650    _2
$a srovnávací genomová hybridizace $7 D055028
650    12
$a variabilita počtu kopií segmentů DNA $7 D056915
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a nádory ledvin $x diagnóza $x genetika $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tretiakova, Maria $u Department of Pathology, University of Washington, Seattle, WA, USA.
700    1_
$a Pivovarcikova, Kristyna $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.
700    1_
$a Alaghehbandan, Reza $u Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC, Canada.
700    1_
$a Perez Montiel, Delia $u Department of Pathology, Institute Nacional de Cancerologia, Mexico City, Mexico.
700    1_
$a Ulamec, Monika $u Ljudevit Jurak Pathology Department, University Clinical Hospital "Sestre milosrdnice", Pathology Department, School of Dental Medicine, University of Zagreb, Croatia.
700    1_
$a Osunkoya, Adeboye $u Department of Pathology, Emory Hospital, Atlanta, USA.
700    1_
$a Trpkov, Kiril $u Department of Pathology and Laboratory Medicine, Calgary Laboratory Services and University of Calgary, Calgary, AB, Canada.
700    1_
$a Yuan, Gao $u Department of Pathology and Laboratory Medicine, Calgary Laboratory Services and University of Calgary, Calgary, AB, Canada.
700    1_
$a Grossmann, Petr $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.
700    1_
$a Sperga, Maris $u Department of Pathology, University of Split, Croatia.
700    1_
$a Ferak, Ivan $u Department of Pathology, AGEL, Novy Jicin, Czech Republic.
700    1_
$a Rogala, Joanna $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.
700    1_
$a Mareckova, Jana $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.
700    1_
$a Pitra, Tomas $u Department of Urology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.
700    1_
$a Kolar, Jiri $u Department of Urology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.
700    1_
$a Michal, Michal $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.
700    1_
$a Hes, Ondrej $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic. Electronic address: hes@medima.cz.
773    0_
$w MED00166541 $t Annals of diagnostic pathology $x 1532-8198 $g Roč. 44, č. - (2020), s. 151448
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31918172 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154153 $b ABA008
999    __
$a ok $b bmc $g 1608870 $s 1119715
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 44 $c - $d 151448 $e 20191214 $i 1532-8198 $m Annals of diagnostic pathology $n Ann. diagn. pathol. $x MED00166541
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...